Chemical structure of "compound 10" BMS TGFβR inhibitor prodrug

tumor specific prodrug of TGFβR inhibitor

QW dosing, improved tumor-to-heart ratio

BMS-986260 prodrug w/ self-immolative link.

Journal of Medicinal Chemistry

Bristol Myers Squibb, Princeton, NJ

The BMS TGFβR inhibitor prodrug, “compound 10,” demonstrates antitumor efficacy comparable to the parent compound (BMS-986260) in a syngeneic model with once-weekly dosing, while reducing the systemic exposure of…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.